Study type: In vivo/preclinical · Status: Verified against declared source

Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection

2021

Study scale: These experiments were then repeated with the same groups and dosing schedule, and the number of mice was increased to 12 in each group for next analysis.

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Beta-4 (TB500): Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

DBT cells were cultured at 37°C in an atmosphere containing 5% CO2 in DMEM containing 5% FBS in culture flasks filled to 90% capacity.

Scale or participants

These experiments were then repeated with the same groups and dosing schedule, and the number of mice was increased to 12 in each group for next analysis.

Key findings

Coronaviruses (CoVs) are enveloped and harbor an unusually large (30–32 kb) positive-strand linear RNA genome.

Limitations and uncertainty

As shown in Table 1, on day 3 postinfection, the concentrations of 18 of 23 cytokines in the sera of both the placebo and rhTβ4 groups were significantly increased vs normal values (P < 0.05).

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.